{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:46:52Z","timestamp":1756309612858,"version":"3.40.5"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T00:00:00Z","timestamp":1659744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s40120-022-00385-1","type":"journal-article","created":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T16:02:45Z","timestamp":1659801765000},"page":"1595-1607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Three Newly Recognized Likely Pathogenic Gene Variants Associated with Hereditary Transthyretin Amyloidosis"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-6750","authenticated-orcid":false,"given":"Jignesh K.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Chamberlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Antolik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tami","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind","family":"Narayana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,6]]},"reference":[{"issue":"1","key":"385_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jns.12153","volume":"21","author":"I Conceicao","year":"2016","unstructured":"Conceicao I, Gonzalez-Duarte A, Obici L, et al. \u201cRed-flag\u201d symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5\u20139.","journal-title":"J Peripher Nerv Syst"},{"key":"385_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1750-1172-8-31","volume":"8","author":"Y Ando","year":"2013","unstructured":"Ando Y, Coelho T, Berk JL, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.","journal-title":"Orphanet J Rare Dis"},{"key":"385_CR3","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04889-2","author":"F Manganelli","year":"2020","unstructured":"Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D. Hereditary transthyretin amyloidosis overview. Neurol Sci. 2020. https:\/\/doi.org\/10.1007\/s10072-020-04889-2.","journal-title":"Neurol Sci"},{"key":"385_CR4","volume-title":"Hereditary transthyretin amyloidosis. Gene Reviews","author":"Y Sekijima","year":"2018","unstructured":"Sekijima Y. Hereditary transthyretin amyloidosis. Gene Reviews. Seattle: University of Washington; 2018."},{"issue":"1","key":"385_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maurer MS, Suhr OB. THAOS\u2014The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63\u201376.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"385_CR6","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1371","volume":"9","author":"MA Gertz","year":"2019","unstructured":"Gertz MA, Mauermann ML, Grogan M, Coelho T. Advances in the treatment of hereditary transthyretin amyloidosis: a review. Brain Behav. 2019;9(9): e01371.","journal-title":"Brain Behav"},{"issue":"7 suppl","key":"385_CR7","first-page":"S107","volume":"23","author":"MA Gertz","year":"2017","unstructured":"Gertz MA. Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care. 2017;23(7 suppl):S107\u201312.","journal-title":"Am J Manag Care"},{"issue":"2","key":"385_CR8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ahj.2012.04.015","volume":"164","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Maurer MS, Judge DP, et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164(2):222\u20138.e1.","journal-title":"Am Heart J"},{"key":"385_CR9","unstructured":"Rowczenio D, Wechalekar A. Mutations in hereditary amyloidosis. 2022. http:\/\/amyloidosismutations.com\/mut-attr.php."},{"issue":"12","key":"385_CR10","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1474-4422(11)70246-0","volume":"10","author":"V Plante-Bordeneuve","year":"2011","unstructured":"Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086\u201397.","journal-title":"Lancet Neurol"},{"key":"385_CR11","first-page":"1","volume":"2019","author":"I Conceicao","year":"2019","unstructured":"Conceicao I, Damy T, Romero M, et al. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid. 2019;2019:1\u20137.","journal-title":"Amyloid"},{"key":"385_CR12","first-page":"1","volume":"2020","author":"F Gorram","year":"2020","unstructured":"Gorram F, Olsson M, Alarcon F, Nuel G, Anan I, Plant\u00e9-Bordeneuve V. New data on the genetic profile and penetrance of hereditary Val30Met transthyretin amyloidosis in Sweden. Amyloid. 2020;2020:1\u20137.","journal-title":"Amyloid"},{"key":"385_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116813","volume":"414","author":"M Ueda","year":"2020","unstructured":"Ueda M, Sekijima Y, Koike H, et al. Monitoring of asymptomatic family members at risk of hereditary transthyretin amyloidosis for early intervention with disease-modifying therapies. J Neurol Sci. 2020;414: 116813.","journal-title":"J Neurol Sci"},{"issue":"1","key":"385_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1136\/jmg.35.1.23","volume":"35","author":"K Yamamoto","year":"1998","unstructured":"Yamamoto K, Ikeda S, Hanyu N, Takeda S, Yanagisawa N. A pedigree analysis with minimised ascertainment bias shows anticipation in Met30-transthyretin related familial amyloid polyneuropathy. J Med Genet. 1998;35(1):23\u201330.","journal-title":"J Med Genet"},{"issue":"3","key":"385_CR15","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1006\/bbrc.2000.2554","volume":"270","author":"MR Almeida","year":"2000","unstructured":"Almeida MR, Alves IL, Terazaki H, Ando Y, Saraiva MJ. Comparative studies of two transthyretin variants with protective effects on familial amyloidotic polyneuropathy: TTR R104H and TTR T119M. Biochem Biophys Res Commun. 2000;270(3):1024\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"385_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1006\/bbrc.1999.1514","volume":"264","author":"H Terazaki","year":"1999","unstructured":"Terazaki H, Ando Y, Misumi S, et al. A novel compound heterozygote (FAP ATTR Arg104His\/ATTR Val30Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels. Biochem Biophys Res Commun. 1999;264(2):365\u201370.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"385_CR17","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/j.1432-1033.1997.00662.x","volume":"249","author":"I Longo Alves","year":"1997","unstructured":"Longo Alves I, Hays MT, Saraiva MJ. Comparative stability and clearance of [Met30]transthyretin and [Met119]transthyretin. Eur J Biochem. 1997;249(3):662\u20138.","journal-title":"Eur J Biochem"},{"issue":"2","key":"385_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/13506120600722449","volume":"13","author":"Y Sekijima","year":"2006","unstructured":"Sekijima Y, Dendle MT, Wiseman RL, White JT, D\u2019Haeze W, Kelly JW. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression. Amyloid. 2006;13(2):57\u201366.","journal-title":"Amyloid"},{"issue":"5539","key":"385_CR19","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1126\/science.1062245","volume":"293","author":"P Hammarstr\u00f6m","year":"2001","unstructured":"Hammarstr\u00f6m P, Schneider F, Kelly JW. Trans-suppression of misfolding in an amyloid disease. Science. 2001;293(5539):2459\u201362.","journal-title":"Science"},{"issue":"1","key":"385_CR20","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12875-020-01252-4","volume":"21","author":"M Gertz","year":"2020","unstructured":"Gertz M, Adams D, Ando Y, et al. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Fam Pract. 2020;21(1):198.","journal-title":"BMC Fam Pract"},{"issue":"suppl 1","key":"385_CR21","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1097\/WCO.0000000000000289","volume":"29","author":"D Adams","year":"2016","unstructured":"Adams D, Suhr OB, Hund E, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29(suppl 1):S14-26.","journal-title":"Curr Opin Neurol"},{"issue":"3","key":"385_CR22","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1093\/jlb\/lsx038","volume":"4","author":"L Hoffman-Andrews","year":"2018","unstructured":"Hoffman-Andrews L. The known unknown: the challenges of genetic variants of uncertain significance in clinical practice. J Law Biosci. 2018;4(3):648\u201357.","journal-title":"J Law Biosci"},{"issue":"1","key":"385_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13073-019-0688-9","volume":"11","author":"SM Harrison","year":"2019","unstructured":"Harrison SM, Rehm HL. Is \u2018likely pathogenic\u2019 really 90% likely? Reclassification data in ClinVar. Genome Med. 2019;11(1):72.","journal-title":"Genome Med"},{"issue":"5","key":"385_CR24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"},{"key":"385_CR25","unstructured":"Khella S, Bumma N, Gabriel A. Patients with hereditary transthyretin amyloidosis: insights from a genetic testing program. In: Virtual; XVII International Symposium on Amyloidosis; 2020."},{"issue":"4","key":"385_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.2144\/btn-2018-0179","volume":"67","author":"M Khurshed","year":"2019","unstructured":"Khurshed M, Molenaar RJ, van Noorden CJ. A simple in silico approach to generate gene-expression profiles from subsets of cancer genomics data. Biotechniques. 2019;67(4):172\u20136.","journal-title":"Biotechniques"},{"key":"385_CR27","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1476-4598-6-50","volume":"6","author":"D Murray","year":"2007","unstructured":"Murray D, Doran P, MacMathuna P, Moss AC. In silico gene expression analysis\u2013an overview. Mol Cancer. 2007;6:50.","journal-title":"Mol Cancer"},{"issue":"2","key":"385_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1111\/j.1432-1033.1995.563_b.x","volume":"234","author":"G Zanotti","year":"1995","unstructured":"Zanotti G, D\u2019Acunto MR, Malpeli G, Folli C, Berni R. Crystal structure of the transthyretin\u2013retinoic-acid complex. Eur J Biochem. 1995;234(2):563\u20139.","journal-title":"Eur J Biochem"},{"key":"385_CR29","doi-asserted-by":"publisher","first-page":"W526","DOI":"10.1093\/nar\/gkh468","volume":"32","author":"DE Kim","year":"2004","unstructured":"Kim DE, Chivian D, Baker D. Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res. 2004;32:W526\u201331.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"385_CR30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1006\/jmbi.2000.4042","volume":"302","author":"C Notredame","year":"2000","unstructured":"Notredame C, Higgins DG, Heringa J. T-Coffee: a novel method for fast and accurate multiple sequence alignment. J Mol Biol. 2000;302(1):205\u201317.","journal-title":"J Mol Biol"},{"key":"385_CR31","doi-asserted-by":"publisher","first-page":"W382","DOI":"10.1093\/nar\/gki387","volume":"33","author":"J Schymkowitz","year":"2005","unstructured":"Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an online force field. Nucleic Acids Res. 2005;33:W382\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"suppl 8","key":"385_CR32","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1186\/1471-2105-10-S8-S8","volume":"10","author":"Y Bromberg","year":"2009","unstructured":"Bromberg Y, Rost B. Correlating protein function and stability through the analysis of single amino acid substitutions. BMC Bioinformatics. 2009;10(suppl 8):S8.","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"385_CR33","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jmb.2007.03.069","volume":"369","author":"N Tokuriki","year":"2007","unstructured":"Tokuriki N, Stricher F, Schymkowitz J, Serrano L, Tawfik DS. The stability effects of protein mutations appear to be universally distributed. J Mol Biol. 2007;369(5):1318\u201332.","journal-title":"J Mol Biol"},{"key":"385_CR34","doi-asserted-by":"publisher","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","volume":"42","author":"MJ Landrum","year":"2014","unstructured":"Landrum MJ, Lee JM, Riley GR, et al. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42:D980\u20135.","journal-title":"Nucleic Acids Res"},{"issue":"4154","key":"385_CR35","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1126\/science.185.4154.862","volume":"185","author":"R Grantham","year":"1974","unstructured":"Grantham R. Amino acid difference formula to help explain protein evolution. Science. 1974;185(4154):862\u20134.","journal-title":"Science"},{"issue":"3","key":"385_CR36","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/humu.23158","volume":"38","author":"BJ Feng","year":"2017","unstructured":"Feng BJ. PERCH: A unified framework for disease gene prioritization. Hum Mutat. 2017;38(3):243\u201351.","journal-title":"Hum Mutat"},{"issue":"3","key":"385_CR37","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3109\/13506129.2013.797890","volume":"20","author":"E Ihse","year":"2013","unstructured":"Ihse E, Rapezzi C, Merlini G, et al. Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid. 2013;20(3):142\u201350.","journal-title":"Amyloid"},{"issue":"9","key":"385_CR38","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1038\/ejhg.2017.95","volume":"25","author":"A Iorio","year":"2017","unstructured":"Iorio A, De Lillo A, De Angelis F, et al. Non-coding variants contribute to the clinical heterogeneity of TTR amyloidosis. Eur J Hum Genet. 2017;25(9):1055\u201360.","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"385_CR39","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1212\/WNL.41.6.893","volume":"41","author":"S Ii","year":"1991","unstructured":"Ii S, Minnerath S, Ii K, Dyck PJ, Sommer SS. Two-tiered DNA-based diagnosis of transthyretin amyloidosis reveals two novel point mutations. Neurology. 1991;41(6):893\u20138.","journal-title":"Neurology"},{"issue":"4","key":"385_CR40","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3109\/13506129909007341","volume":"6","author":"N Tachibana","year":"1999","unstructured":"Tachibana N, Tokuda T, Yoshida K, et al. Usefulness of MALDI\/TOF mass spectrometry of immunoprecipitated serum variant transthyretin in the diagnosis of familial amyloid polyneuropathy. Amyloid. 1999;6(4):282\u20138.","journal-title":"Amyloid"},{"key":"385_CR41","unstructured":"National Center for Biotechnology Information. NM_000371.3(TTR):c.173A>C (p.Asp58Ala) Pathogenic. In: Bethesda, MD: National Center for Biotechnology Information; 2021."},{"issue":"2","key":"385_CR42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/ahg.12101","volume":"79","author":"MA Jang","year":"2015","unstructured":"Jang MA, Lee GY, Kim K, et al. Asp58Ala is the predominant mutation of the TTR gene in Korean patients with hereditary transthyretin-related amyloidosis. Ann Hum Genet. 2015;79(2):99\u2013107.","journal-title":"Ann Hum Genet"},{"issue":"4","key":"385_CR43","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3109\/13506129909007340","volume":"6","author":"M Kishikawa","year":"1999","unstructured":"Kishikawa M, Nakanishi T, Miyazaki A, et al. A new amyloidogenic transthyretin variant, [D38A], detected by electrospray ionization\/mass spectrometry. Amyloid. 1999;6(4):278\u201381.","journal-title":"Amyloid"},{"issue":"4","key":"385_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4250\/jcu.2012.20.4.209","volume":"20","author":"HJ Cho","year":"2012","unstructured":"Cho HJ, Yoon JY, Bae MH, et al. Familial transthyretin amyloidosis with variant Asp38Ala presenting with orthostatic hypotension and chronic diarrhea. J Cardiovasc Ultrasound. 2012;20(4):209\u201312.","journal-title":"J Cardiovasc Ultrasound"},{"issue":"23","key":"385_CR45","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1056\/NEJMoa013354","volume":"346","author":"HJ Lachmann","year":"2002","unstructured":"Lachmann HJ, Booth DR, Booth SE, et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med. 2002;346(23):1786\u201391.","journal-title":"N Engl J Med"},{"issue":"1","key":"385_CR46","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/jns.12112","volume":"20","author":"C Lavigne Moreira","year":"2015","unstructured":"Lavigne Moreira C, Marques VD, Louren\u00e7o CM, et al. Transthyretin Asp38Tyr: a new mutation associated to a late onset neuropathy. J Peripher Nerv Syst. 2015;20(1):60\u20132.","journal-title":"J Peripher Nerv Syst"},{"issue":"7809","key":"385_CR47","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski KJ, Francioli LC, Tiao G, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581(7809):434\u201343.","journal-title":"Nature"},{"issue":"8","key":"385_CR48","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","volume":"85","author":"D Adams","year":"2015","unstructured":"Adams D, Coelho T, Obici L, et al. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology. 2015;85(8):675\u201382.","journal-title":"Neurology"},{"issue":"7","key":"385_CR49","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1111\/j.1742-4658.2007.05712.x","volume":"274","author":"X Hou","year":"2007","unstructured":"Hou X, Aguilar MI, Small DH. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J. 2007;274(7):1637\u201350.","journal-title":"FEBS J"},{"issue":"1","key":"385_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/03009734.2015.1122687","volume":"121","author":"B Pilebro","year":"2016","unstructured":"Pilebro B, Suhr OB, Naslund U, Westermark P, Lindqvist P, Sundstrom T. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups J Med Sci. 2016;121(1):17\u201324.","journal-title":"Ups J Med Sci"},{"issue":"5","key":"385_CR51","first-page":"1027","volume":"50","author":"MJ Saraiva","year":"1992","unstructured":"Saraiva MJ, Almeida Mdo R, Sherman W, et al. A new transthyretin mutation associated with amyloid cardiomyopathy. Am J Hum Genet. 1992;50(5):1027\u201330.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"385_CR52","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3109\/13506120009146252","volume":"7","author":"T Janunger","year":"2000","unstructured":"Janunger T, Anan I, Holmgren G, et al. Heart failure caused by a novel amyloidogenic mutation of the transthyretin gene: ATTR Ala45Ser. Amyloid. 2000;7(2):137\u201340.","journal-title":"Amyloid"},{"key":"385_CR53","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.carpath.2017.04.002","volume":"29","author":"SHC Klaassen","year":"2017","unstructured":"Klaassen SHC, Lemmink HH, Bijzet J, et al. Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G). Cardiovasc Pathol. 2017;29:19\u201322.","journal-title":"Cardiovasc Pathol"},{"issue":"1","key":"385_CR54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1172\/JCI112573","volume":"78","author":"MR Wallace","year":"1986","unstructured":"Wallace MR, Dwulet FE, Conneally PM, Benson MD. Biochemical and molecular genetic characterization of a new variant prealbumin associated with hereditary amyloidosis. J Clin Invest. 1986;78(1):6\u201312.","journal-title":"J Clin Invest"},{"issue":"2","key":"385_CR55","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/13506129.2015.1019610","volume":"22","author":"PL Swiecicki","year":"2015","unstructured":"Swiecicki PL, Zhen DB, Mauermann ML, et al. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Amyloid. 2015;22(2):123\u201331.","journal-title":"Amyloid"},{"issue":"suppl 1","key":"385_CR56","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3109\/13506129.2012.665400","volume":"19","author":"SR Zeldenrust","year":"2012","unstructured":"Zeldenrust SR. Genotype\u2013phenotype correlation in FAP. Amyloid. 2012;19(suppl 1):22\u20134.","journal-title":"Amyloid"},{"issue":"12","key":"385_CR57","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1002\/elps.200600840","volume":"28","author":"K Altland","year":"2007","unstructured":"Altland K, Benson MD, Costello CE, et al. Genetic microheterogeneity of human transthyretin detected by IEF. Electrophoresis. 2007;28(12):2053\u201364.","journal-title":"Electrophoresis"},{"issue":"2","key":"385_CR58","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/jpm9020029","volume":"9","author":"SB Haga","year":"2019","unstructured":"Haga SB, Kim E, Myers RA, Ginsburg GS. Primary care physicians\u2019 knowledge, attitudes, and experience with personal genetic testing. J Pers Med. 2019;9(2):29.","journal-title":"J Pers Med"},{"issue":"4","key":"385_CR59","doi-asserted-by":"publisher","first-page":"257","DOI":"10.22454\/FamMed.2018.265534","volume":"45","author":"AG Mainous 3rd","year":"2013","unstructured":"Mainous AG 3rd, Johnson SP, Chirina S, Baker R. Academic family physicians\u2019 perception of genetic testing and integration into practice: a CERA study. Fam Med. 2013;45(4):257\u201362.","journal-title":"Fam Med"},{"key":"385_CR60","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","volume":"70","author":"CF Bennett","year":"2019","unstructured":"Bennett CF. Therapeutic antisense oligonucleotides are coming of age. Annu Rev Med. 2019;70:307\u201321.","journal-title":"Annu Rev Med"},{"issue":"1","key":"385_CR61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2217\/nmt-2018-0037","volume":"9","author":"MD Benson","year":"2019","unstructured":"Benson MD, Dasgupta NR, Monia BP. Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis. Neurodegener Dis Manag. 2019;9(1):25\u201330.","journal-title":"Neurodegener Dis Manag"},{"issue":"3","key":"385_CR62","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/gim.2017.207","volume":"20","author":"S Macklin","year":"2018","unstructured":"Macklin S, Durand N, Atwal P, Hines S. Observed frequency and challenges of variant reclassification in a hereditary cancer clinic. Genet Med. 2018;20(3):346\u201350.","journal-title":"Genet Med"},{"issue":"2","key":"385_CR63","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jgc4.1336","volume":"30","author":"RE VanDyke","year":"2021","unstructured":"VanDyke RE, Hashimoto S, Morales A, Pyatt RE, Sturm AC. Impact of variant reclassification in the clinical setting of cardiovascular genetics. J Genet Couns. 2021;30(2):503\u201312.","journal-title":"J Genet Couns"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00385-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00385-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00385-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T02:07:11Z","timestamp":1666490831000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00385-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,6]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00385-1","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"type":"print","value":"2193-8253"},{"type":"electronic","value":"2193-6536"}],"subject":[],"published":{"date-parts":[[2022,8,6]]},"assertion":[{"value":"13 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}